NCT01358071 - Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer | Biotech Hunter

Enrollment

119

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Ovarian Cancer

Interventions

DRUG

NGR-hTNF

NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion weekly or every 3 or 4 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs

DRUG

Pegylated liposomal doxorubicin

50 mg/m² iv every 4 weeks until confirmed evidence of disease progression

DRUG

Doxorubicin

60 mg/m² iv every 3 weeks for a maximum of 8 cycles

Trial Locations (8)

20132

Ospedale San Raffaele, Milan

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

20141

Istituto Europeo di Oncologia, Milan

80131

"Istituto Nazionale Tumori IRCCS Fondazione Giovanni Pascale", Naples

06156

Ospedale S. Maria della Misericordia, Perugia

00168

"Policlinico Universitario Agostino Gemelli", Rome

G12 0YN

Beatson Oncology Centre, Gartnavel Hospital, Glasgow

CH63 4JY

Clatterbridge Centre for Oncology, Bebington